Ovarian cancer causes more deaths each year than all other gynecological cancers combined. The number of prevalent ovarian cancer cases in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will increase at a rate of 1.0% per year between 2000 and 2010. However, sales for ovarian cancer therapies in these markets will grow much more robustly-by almost 5% per year. Ovarian Cancer is a new Decision Resources study that reveals emerging trends in the treatment of this disease that will fuel market growth.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) Expanded Use of Second-Line Therapies Will Boost the Market
Over the 2000-2010 forecast period of this study, treatment of relapsed or treatment-refractory disease is likely to involve a greater use of combination therapy, which generally consists of a first- and a second-line drug.
Market Outlook-New Drugs Will Displace the Old
We estimate that sales of drugs to treat ovarian cancer will grow by nearly 5% per year over the forecast period, reflecting the slow but steady increase in the ovarian cancer population in the major-market countries. This market growth also reflects the likelihood that physicians in all these countries will use a greater variety of newer, more expensive drugs in patients with relapsed or treatment-refractory disease, rather than treating these patients with older, less expensive agents.
Launch of Premium-Priced Monoclonal Antibodies Will Significantly Impact Market Growth
Within the next five years, monoclonal antibodies in late-stage development programs will become available for use in ovarian cancer. Trastuzumab (Genentech/Roche's Herceptin), already approved for metastatic breast cancer that overexpresses the oncogene HER2, and pemtumomab (Antisoma/Abbott Laboratories' Theragyn) will have a major impact on the ovarian cancer market, each reaching sales of almost $90 million by 2010 for the treatment of ovarian cancer.
Ovarian Cancer offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this disease. This study is part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or firstname.lastname@example.org.
In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or email@example.com.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, +1-781-296-2553,